Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: A scoping review
Antiviral Therapy, 2023 Background: Biktarvy is approved for use in HIV-1 infection in both treatment-naïve and treatment-experienced individuals, after a series of successful phase III trials.
Collins C Iwuji
exaly +7 more sources
Assessment of Gastrointestinal Adverse Effects during the First Six Months of “Biktarvy” Antiretroviral Therapy: Age-Related Patterns and Their Relation with Changes of 5 kg Weight Loss/Gain in the Initial Treatment Period [PDF]
Diseases, 2023 Background: The battle against HIV has led to the development of antiretroviral therapy (ART), including BIKTARVY®, which combines three potent agents.
Madalina-Ianca Suba +7 more
doaj +5 more sources
Comparative safety profile of biktarvy: insights from a clinical cohort and the FAERS database. [PDF]
Frontiers in PharmacologyBackgroundBiktarvy, a second-generation integrase strand-transfer inhibitor, is approved for treating human immunodeficiency virus (HIV) in patients with no known resistance to its components.
Linli Xie, Qingqing Tian
exaly +5 more sources
Assessment of the impact of the new blister packaging of Biktarvy® (B/F/TAF) on treatment satisfaction of people living with HIV [PDF]
PLoS ONEBackgroundAntiretroviral therapy (ART) is highly effective in people living with HIV (PLHIV), but its success depends on treatment satisfaction and adherence.
Francisco Antunes, Abigail Ferreira
exaly +7 more sources
Newly Diagnosed HIV in an Octogenarian Woman: A Case Report on Delayed Diagnosis in Vulnerable Populations [PDF]
Clinical Case ReportsHIV infection in elderly individuals is often under recognized due to stigma, low clinical suspicion, and communication barriers. We present the case of an 85‐year‐old woman from a rural area who was diagnosed with HIV during staging workup for newly ...
HeeKyoung Choi +3 more
doaj +4 more sources
A Case Report on Lactic Acidosis Induced by Biktarvy in a Patient With Renal Impairment: A Rare Complication of Antiretroviral Therapy [PDF]
Journal of the International Association of Providers of AIDS CareBiktarvy, a once-daily combination of bictegravir, emtricitabine, and tenofovir alafenamide (TAF), is a highly effective antiretroviral therapy for HIV management. Although well-tolerated, rare but serious complications such as lactic acidosis can occur,
Shuja Abdul Karim Khan
exaly +6 more sources
Correction: Comparative safety profile of biktarvy: insights from a clinical cohort and the FAERS database [PDF]
Frontiers in PharmacologyXinmei Pan +4 more
doaj +4 more sources
Acute Pancreatitis Secondary to Hyperlipidemia After Exposure to Biktarvy and Alcohol in a HIV-Positive Patient:A Case Report [PDF]
International Medical Case Reports JournalRongrong Zheng, Zhongdong Zhang, Jun Yan, Feng Li, Jinchuan Shi The Second Infectious Disease Department, Xixi Hospital of Hangzhou, Hangzhou, 310023, Peopleâs Republic of ChinaCorrespondence: Jinchuan Shi, The Second Infectious Disease Department, Xixi Hospital of Hangzhou, No.
Jinchuan Shi
exaly +6 more sources
A crucial role for novel miR-12137-3p in supporting weight gain in treatment naïve HIV-infected patients on antiretroviral therapies [PDF]
Journal of Translational MedicineBackground MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression post-transcriptionally. MiRNAs are implicated in diverse biological processes.
Niska Majumdar +5 more
doaj +2 more sources
A possible case of bictegravir-associated severe unconjugated hyperbilirubinemia
AIDS Research and Therapy, 2023 Background Bictegravir (BIC) co-formulated with emtricitabine (FTC) and tenofovir alafenamide (TAF) is approved by Federal Food and Drug Administration in 2018 for both treatment-naïve and experienced persons living with HIV (PLWH).
Kanak Parmar +3 more
doaj +1 more source